Freenome Reports Q3 2026 Financial Results and Revenue
Health
Earnings
Merger:
Jul 21, 2026
Industry:
MEDICAL LABORATORIES
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Freenome Reports Third Quarter 2026 Financial Results
Brisbane, California, USA -- Freenome, Inc. (NASDAQ: FRNM), a personalized cancer detection company using an AI-driven multiomics platform, reported its financial results for the third quarter ended September 30, 2026, highlighting strong revenue growth driven by the FDA approval of SimpleScreen CRC and its recent public market debut.
... Read on — Members only
About Freenome Holdings, Inc.
Freenome is an early cancer detection company developing blood-based tests to detect cancer when it is most treatable. The company recognizes that no single technology can identify every cancer due to the disease’s inherent heterogeneity. Freenome’s approach combines a multiomics platform that analyzes multiple signals in the blood with artificial intelligence and machine learning to tune into cancer’s subtlest clues, even at the earliest stages of the disease.
